Order Article Reprints

Barve V, Adams N, Stanbery L, Manning L, Horvath S, Wallraven G, Bognar E, Barve M, Nemunaitis J. Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6. Vaccines. 2021; 9(10):1201. https://doi.org/10.3390/vaccines9101201

Barve, Vedin, Ned Adams, Laura Stanbery, Luisa Manning, Staci Horvath, Gladice Wallraven, Ernest Bognar, Minal Barve, and John Nemunaitis. 2021. "Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6" Vaccines 9, no. 10: 1201. https://doi.org/10.3390/vaccines9101201

Barve, V., Adams, N., Stanbery, L., Manning, L., Horvath, S., Wallraven, G., Bognar, E., Barve, M., & Nemunaitis, J. (2021). Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6. Vaccines, 9(10), 1201. https://doi.org/10.3390/vaccines9101201